Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13122993 | 0.92 | TBXA2R (0.80) | TBXA2RPTGDR | |
| SCHEMBL1040649 | 0.88 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL4466127 | 0.84 | TBXA2R (0.79) | TBXA2RPTGDR | |
| SCHEMBL990588 | 0.84 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL18269302 | 0.80 | TBXA2R (0.86) | TBXA2RPTGDR | |
| SCHEMBL13122992 | 0.80 | PTGDR (0.80) | TBXA2RPTGDR | |
| SCHEMBL1255205 | 0.80 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL13638150 | 0.78 | TBXA2R (0.62) | TBXA2RPTGDR | |
| SCHEMBL3148394 | 0.76 | TBXA2R (0.73) | TBXA2RPTGDR | |
| SCHEMBL991147 | 0.74 | PTGDR (1.00) | TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139604-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139604-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, HCAR1, FFAR1 | TBXA2R 37/4885PTGDR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.